Insight Molecular Diagnostics Inc. Common Stock (IMDX) is a publicly traded Healthcare sector company. As of May 21, 2026, IMDX trades at $6.04 with a market cap of $205.04M and a P/E ratio of -3.56. IMDX moved +0.00% today. Year to date, IMDX is -17.14%; over the trailing twelve months it is flat. Its 52-week range spans $2.33 to $8.51. Analyst consensus is buy with an average price target of $10.50. Rallies surfaces IMDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes IMDX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $6.04 |
| Market Cap | $205.04M |
| P/E Ratio | -3.56 |
| EPS | $-1.65 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.51 |
| 52-Week Low | $2.33 |
| Volume | 1.53K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.05M |
| Net Income | $-50.22M |
| Gross Margin | 56.67% |
3 analysts cover IMDX: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.50.